Follow The Filings

ACIU AC Immune

AC Immune earnings company data as of 4:46 AM ET 10/24

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 3 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by ACIU's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ACIU insider trades
  • $31K bought by 1 insider
  • None no sales outside a trading plan
  • $59K sold by 1 insider under 10b5-1 plans
  1. Andrea Pfeifer CEO
    Planned sale
    $28K 10,000 shares at $2.79 0.3% of stake
    Traded May 15 Filed May 18
    ↗
  2. Andrea Pfeifer CEO
    Planned sale
    $31K 10,000 shares at $3.14 0.3% of stake
    Traded Apr 15 Filed Apr 16
    ↗
  3. Andrea Pfeifer CEO
    Buy
    $31K 10,000 shares at $3.14 +0.3% to stake
    Traded Apr 15 Filed Apr 16
    ↗

Also filed in the last 12 months, not counted as buying or selling: 5 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
6-K Filing Doc
6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K Filing Doc
6-K Filing Doc
6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
20-F Filing Doc
6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc
6-K FORM 6-K Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.